Back to Search
Start Over
Patho-Pharmacological Research of Anti-allergic Natural Products Targeting Antihistamine-Sensitive and -Insensitive Allergic Mechanisms.
- Source :
-
Current topics in behavioral neurosciences [Curr Top Behav Neurosci] 2022; Vol. 59, pp. 77-90. - Publication Year :
- 2022
-
Abstract
- Histamine H <subscript>1</subscript> receptor (H1R) has a special up-regulation mechanism by the stimulation of H1R, mediated by protein kinase C-delta (PKCδ) signaling and H1R gene expression, resulting increase in H1R signaling. Increase in H1R mRNA in nasal mucosa was induced after the provocation of nasal hypersensitivity model rats and suppressed by the pre-treatment of antihistamines. Improvement of nasal symptoms and suppression of H1R mRNA expression in nasal mucosa were also observed by the pre-treatment of antihistamines in pollinosis patients. Elucidation of a correlation between symptoms and H1R mRNA level suggests that H1R gene is an allergic disease (AD)-susceptibility gene, targeted by antihistamines. Similar to antihistamines, pre-treatment of Kujin extract, an anti-allergic Kampo medicine improved nasal symptoms and suppressed H1R mRNA expression in nasal hypersensitivity model rats. (-)-Maackiain targeting heat shock protein 90 (Hsp90) was isolated as an inhibitor of PKCδ signaling-mediated H1R gene expression from Kujin extract. In addition to H1R-mediated activation of H1R gene expression as the first mechanism, nuclear factor of activated T-cells (NFAT)-mediated IL-9 gene expression is suggested to participate to allergic symptoms as the second mechanism insensitive to antihistamines. Pyrogallol and proanthocyanidin suppressing IL-9 gene expression were discovered from Awa-tea and lotus root knots, respectively. Combination therapy using medicines suppressing both H1R gene expression and IL-9 gene expression is promising for outstanding alleviation of AD. Multifactorial diseases involving H1R gene expression may be treated by the combination therapy with antihistamine and complementary drugs, and diseases involving PKCδ signaling may be treated by drugs targeting Hsp90.<br /> (© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.)
- Subjects :
- Animals
Heat-Shock Proteins therapeutic use
Histamine metabolism
Histamine therapeutic use
Histamine Antagonists pharmacology
Histamine Antagonists therapeutic use
Humans
Interleukin-9 therapeutic use
Protein Kinase C-delta metabolism
Protein Kinase C-delta therapeutic use
Pyrogallol therapeutic use
RNA, Messenger genetics
RNA, Messenger metabolism
RNA, Messenger therapeutic use
Receptors, Histamine H1 genetics
Receptors, Histamine H1 metabolism
Receptors, Histamine H1 therapeutic use
Tea
Anti-Allergic Agents pharmacology
Anti-Allergic Agents therapeutic use
Biological Products therapeutic use
Hypersensitivity drug therapy
Hypersensitivity genetics
Proanthocyanidins therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1866-3370
- Volume :
- 59
- Database :
- MEDLINE
- Journal :
- Current topics in behavioral neurosciences
- Publication Type :
- Academic Journal
- Accession number :
- 34647283
- Full Text :
- https://doi.org/10.1007/7854_2021_255